α4 nicotinic acetylcholine receptor modulated by galantamine on nigrostriatal terminals regulates dopamine receptor-mediated rotational behavior

Neurochemistry International

Volumn 94, Issue , 2016, Pages 74-81

  Inden, Masatoshi ^a   Takata, Kazuyuki ^b   Yanagisawa, Daijiro ^c   Ashihara, Eishi ^b   Tooyama, Ikuo ^c   Shimohama, Shun ^d   Kitamura, Yoshihisa ^b,e  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^d SAPPORO MEDICAL UNIVERSITY   (Japan)

^e RITSUMEIKAN UNIVERSITY   (Japan)

Author keywords

6 Hydroxydopamine; Dopamine; Galantamine; Nicotinic acetylcholine receptor; Parkinson's disease

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 4 CHLORO N (3 QUINUCLIDINYL)BENZAMIDE; APOMORPHINE; DOPAMINE RECEPTOR; FLUPENTIXOL; GALANTAMINE; MECAMYLAMINE; METHAMPHETAMINE; METHYLLYCACONITINE; NICOTINE; NICOTINIC RECEPTOR ALPHA4; NOMIFENSINE; OXIDOPAMINE; QUINPIROLE; DOPAMINE RECEPTOR STIMULATING AGENT; NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA4 SUBUNIT; NICOTINIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEREOLOGY; ANIMAL; DRUG EFFECTS; LOCOMOTION; PHYSIOLOGY; SUBSTANTIA NIGRA; WISTAR RAT;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; CORPUS STRIATUM; DOPAMINE AGONISTS; GALANTAMINE; LOCOMOTION; MALE; OXIDOPAMINE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE; RECEPTORS, NICOTINIC; SUBSTANTIA NIGRA;

EID: 84975778603     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2016.02.008     Document Type: Article

References (40)

1. T. Bordia, C. Campos, J.M. McIntosh, and M. Quik Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization J. Pharmacol. Exp. Ther. 333 2010 929 938
2. T. Bordia, M. McGregor, R.L. Papke, M.W. Decker, J.M. McIntosh, and M. Quik The α7 nicotinic receptor agonist ABT-107 protects against l damage in rats with unilateral 6-hydroxydopamine lesions Exp. Neurol. 263 2015 277 284
3. P. Davies, and A.J. Maloney Selective loss of central cholinergic neurons in Alzheimer's disease Lancet 2 1976 1403
4. S. Fahn How do you treat motor complications in Parkinson's disease: medicine, surgery, or both? Ann. Neurol. 64 2008 S56 S64
5. P. Faure, S. Tolu, S. Valverde, and J. Naudé Role of nicotinic acetylcholine receptors in regulating dopamine neuron activity Neuroscience 282C 2014 86 100
6. H. Geerts, L. Finkel, R. Carr, and A. Spiros Nicotinic receptor modulation: Advantages for successful Alzheimer's disease therapy J. Neural. Transm. 62 2002 203 216
7. C. Gotti, M. Zoli, and F. Clementi Brain nicotinic acetylcholine receptors: native subtypes and their relevance Trends Pharmacol. Sci. 27 2006 482 491
8. C.M. Hernandez, D.A. Gearhart, V. Parikh, E.J. Hohnadel, L.W. Davis, M.L. Middlemore, S.P. Warsi, J.L. Waller, and A.V. Terry Jr. Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats J. Pharmacol. Exp. Ther. 316 2006 679 694
9. L.Z. Huang, S.R. Grady, and M. Quik Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2∗nicotinic receptors J. Pharmacol. Exp. Ther. 338 2011 932 941
10. M. Inden, M. Abe, H. Minamino, K. Takata, K. Yoshimoto, I. Tooyama, and Y. Kitamura Effect of selective serotonin reuptake inhibitors via 5-HT1A receptors on L-DOPA-induced rotational behavior in a hemiparkinsonian rat model J. Pharmacol. Sci. 119 2012 10 19
11. M. Inden, Y. Kitamura, J. Kondo, K. Hayashi, T. Yanagida, K. Takata, D. Tsuchiya, D. Yanagisawa, K. Nishimura, T. Taniguchi, S. Shimohama, H. Sugimoto, and A. Akaike Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats J. Neurochem. 95 2005 950 961
12. M. Inden, T. Taira, Y. Kitamura, T. Yanagida, D. Tsuchiya, K. Takata, D. Yanagisawa, K. Nishimura, T. Taniguchi, Y. Kiso, K. Yoshimoto, T. Agatsuma, S. Koide-Yoshida, S.M. Iguchi-Ariga, S. Shimohama, and H. Ariga PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson's disease rat model Neurobiol. Dis. 24 2006 144 158
13. J.N. Joyce, A.M. Murray, H.I. Hurtig, G.L. Gottlieb, and J.Q. Trojanowski Loss of dopamine D2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease Neuropsychopharmacology 19 1998 472 480
14. T. Kihara, H. Sawada, T. Nakamizo, R. Kanki, H. Yamashita, A. Maelicke, and S. Shimohama Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity Biochem. Biophys. Res. Commun. 325 2004 976 982
15. A. Maelicke, and E.X. Albuquerque Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease Eur. J. Pharmacol. 393 2000 165 170
16. A. Maelicke, T. Coban, A. Storch, A. Schrattenholz, E.F. Pereira, and E.X. Albuquerque Allosteric modulation of torpedo nicotinic acetylcholine receptor ion channel activity by noncompetitive agonists J. Recept. Signal Transduct. Res. 17 1997 11 28
17. A. Maelicke, M. Samochocki, R. Jostock, A. Fehrenbacher, J. Ludwig, E.X. Albuquerque, and M. Zerlin Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease Biol. Psychiatry 49 2001 279 288
18. R. Nashmi, C. Xiao, P. Deshpande, S. McKinney, S.R. Grady, P. Whiteaker, Q. Huang, T. McClure-Begley, J.M. Lindstrom, C. Labarca, A.C. Collins, M.J. Marks, and H.A. Lester Chronic nicotine cell specifically upregulates functional alpha 4∗nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path J. Neurosci. 27 2007 8202 8218
19. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates second ed. 1986 Academic Press North Ryde, Australia
20. W. Poewe Treatments for Parkinson disease-past achievements and current clinical needs Neurology 72 2009 S65 S73
21. I. Posadas, B. López-Hernández, and V. Ceña Nicotinic receptors in neurodegeneration Curr. Neuropharmacol. 11 2013 298 314
22. M. Quik, H. Cox, N. Parameswaran, K. O'Leary, J.W. Langston, and D. Di Monte Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys Ann. Neurol. 62 2007 588 596
23. M. Quik, L.Z. Huang, N. Parameswaran, T. Bordia, C. Campos, and X.A. Perez Multiple roles for nicotine in Parkinson's disease Biochem. Pharmacol. 78 2009 677 685
24. M.W. Quick, and R.A. Lester Desensitization of neuronal nicotinic receptors J. Neurobiol. 53 2002 457 478
25. M.A. Raskind Update on Alzheimer drugs (galantamine) Neurologist 9 2003 235 240
26. M.A. Raskind, E.R. Peskind, L. Truyen, P. Kershaw, and C.V. Damaraju The cognitive benefits of galantamine are sustained for at least 36 months: A long-term extension trial Arch. Neurol. 61 2004 252 256
27. M.A. Raskind, E.R. Peskind, T. Wessel, and W. Yuan Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group Neurology 54 2000 2261 2268
28. U. Richarz, M. Gaudig, K. Rettig, and B. Schauble Galantamine treatment in outpatients with mild Alzheimer's disease Acta Neurol. Scand. 129 2014 382 392
29. F. Rode, G. Munro, D. Holst, E.Ø. Nielsen, K.B. Troelsen, D.B. Timmermann, L.C. Rønn, and M. Grunnet Positive allosteric modulation of α4β2 nAChR agonist induced behaviour Brain Res. 1458 2012 67 75
30. M. Samochocki, A. Höffle, A. Fehrenbacher, R. Jostock, J. Ludwig, C. Christner, M. Radina, M. Zerlin, C. Ullmer, E.F. Pereira, H. Lübbert, E.X. Albuquerque, and A. Maelicke Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors J. Pharmacol. Exp. Ther. 305 2003 1024 1036
31. S. Shimohama Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models Biol. Pharm. Bull. 32 2009 332 336
32. S. Suzuki, J. Kawamata, T. Matsushita, A. Matsumura, S. Hisahara, K. Takata, Y. Kitamura, W. Kem, and S. Shimohama 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through α7 nicotinic acetylcholine receptor stimulation in rats J. Neurosci. Res. 91 2013 462 471
33. K. Takata, Y. Kitamura, M. Saeki, M. Terada, S. Kagitani, R. Kitamura, Y. Fujikawa, A. Maelicke, H. Tomimoto, T. Taniguchi, and S. Shimohama Galantamine-induced amyloid-β clearance mediated via stimulation of microglial nicotinic acetylcholine receptors J. Biol. Chem. 285 2010 40180 40191
34. H. Takeuchi, T. Yanagida, M. Inden, K. Takata, Y. Kitamura, K. Yamakawa, H. Sawada, Y. Izumi, N. Yamamoto, T. Kihara, K. Uemura, H. Inoue, T. Taniguchi, A. Akaike, R. Takahashi, and S. Shimohama Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models J. Neurosci. Res. 87 2009 576 585
35. A. Taly, P.J. Corringer, D. Guedin, P. Lestage, and J.P. Changeux Nicotinic receptors: Allosteric transitions and therapeutic targets in the nervous system Nat. Rev. Drug Discov. 8 2009 733 750
36. Z. Walker, D.C. Costa, R.W. Walker, K. Shaw, S. Gacinovic, T. Stevens, G. Livingston, P. Ince, I.G. McKeith, and C.L. Katona Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand J. Neurol. Neurosurg. Psychiatry 73 2002 134 140
37. C. Xiao, R. Nashmi, S. McKinney, H. Cai, J.M. McIntosh, and H.A. Lester Chronic nicotine selectively enhances alpha4beta2∗nicotinic acetylcholine receptors in the nigrostriatal dopamine pathway J. Neurosci. 29 2009 12428 12439
38. T. Yanagida, K. Takata, M. Inden, Y. Kitamura, T. Taniguchi, K. Yoshimoto, T. Taira, and H. Ariga Distribution of DJ-1, Parkinson's disease-related protein PARK7, and its alteration in 6-hydroxydopamine-treated hemiparkinsonian rat brain J. Pharmacol. Sci. 102 2006 243 247
39. T. Yanagida, H. Takeuchi, Y. Kitamura, K. Takata, H. Minamino, T. Shibaike, J. Tsushima, K. Kishimoto, H. Yasui, T. Taniguchi, and S. Shimohama Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model Neurosci. Res. 62 2008 254 261
40. L. Zhang, F.M. Zhou, and J.A. Dani Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release Mol. Pharmacol. 66 2004 538 544